Clinical Trial

Soylent in Reducing Gastrostomy Tube Rates in Patients With Locally Advanced Head and Neck Cancer Undergoing Chemoradiotherapy

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This phase II trial studies Soylent in reducing gastrostomy tube rates in patients with head and neck cancer that has spread to nearby tissues or lymph nodes (locally advanced) who are undergoing chemoradiotherapy. Soylent is a liquid meal replacement product that may reduce the risk of malnutrition and gastrostomy placement during or following treatment for head and neck cancer with chemoradiation.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-11-20; most recent amendment 2026-02-03.
Trial Details
NCT Number NCT07242365
Lead Sponsor Jonsson Comprehensive Cancer Center
Collaborators: National Cancer Institute (NCI)
Conditions Locally Advanced Head and Neck Carcinoma
Enrollment 60 participants
Start Date 2017-06-19
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-02-05